These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Experience with neoral cyclosporine through the oral route in liver transplantation. Bilbao I, Lazaro JL, Pou L, Charco R, Hildalgo E, Murio E, Margarit C. Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580 [No Abstract] [Full Text] [Related]
24. Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. Miura S, Okazaki H, Sato T, Amada N, Ohashi Y. Transplant Proc; 1998 Jun; 30(4):1212-3. PubMed ID: 9636492 [No Abstract] [Full Text] [Related]
28. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. Wiesner RH. Transplant Proc; 1998 Jun; 30(4):1399-400. PubMed ID: 9636565 [No Abstract] [Full Text] [Related]
29. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. Bismuth H. Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415 [No Abstract] [Full Text] [Related]
32. Relevance of positive lymphocytotoxic crossmatch and immunosuppressive regimens in the outcome of liver transplants. Charco R, Vargas V, Balsells J, Lázaro JL, Murio E, Jaurrieta E, Martorell J, Margarit C. Transplant Proc; 1997 Feb; 29(1-2):461-2. PubMed ID: 9123082 [No Abstract] [Full Text] [Related]
33. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. Kokado Y, Takahara S, Kyo M, Ichimaru N, Toki K, Wang JD, Okuyama A. Transplant Proc; 1999 Feb; 31(1-2):1151-4. PubMed ID: 10083515 [No Abstract] [Full Text] [Related]
34. Living-related versus living-unrelated kidney transplantation using tacrolimus initial immunosuppression. Braun F, Canelo R, Lorf T, Schütz E, Grupp C, Müller GA, Ringe B. Transplant Proc; 2000 Feb; 32(1):115-6. PubMed ID: 10700989 [No Abstract] [Full Text] [Related]
35. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. Lo CM, Fan ST, Liu CL, Chan KL, Ng IO, Lai CL, Lau GK, Fung SK, Wong J. Transplant Proc; 1998 Nov; 30(7):3587-8. PubMed ID: 9838571 [No Abstract] [Full Text] [Related]
38. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. Salizzoni M, Cavallari A, Risaliti A, Filipponi F, Gerunda GE, Forti D, Fassati LR, Cillo U, Castagneto M, Valente U, Tisone G. Transplant Proc; 2001 May; 33(3):2258-62. PubMed ID: 11377521 [No Abstract] [Full Text] [Related]
39. Long-term follow-up (5 and 10 years) in recipients of HLA identical living related donor kidney grafts receiving continuous cyclosporine compared with azathioprine. MacDonald AS, Belitsky P, Bitter-Suermann H, Lawen J, MacSween M, Kiberd B, West K, McAlister VC. Transplant Proc; 1997 May; 29(1-2):190. PubMed ID: 9122958 [No Abstract] [Full Text] [Related]
40. Kidney transplantation at one center: 1-year results. Haberal M, Bilgin N, Karakayali H, Arslan G, Büyükpamukçu N, Velidedeoğlu E, Turan M, Akkoç H, Moray G, Tezel E. Transplant Proc; 1996 Feb; 28(1):410-1. PubMed ID: 8644295 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]